Park Avenue Securities LLC Purchases 1,911 Shares of Smith & Nephew plc (NYSE:SNN)

Park Avenue Securities LLC grew its position in shares of Smith & Nephew plc (NYSE:SNN) by 12.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,738 shares of the medical equipment provider’s stock after buying an additional 1,911 shares during the quarter. Park Avenue Securities LLC’s holdings in Smith & Nephew were worth $450,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently modified their holdings of the company. Ridgewood Investments LLC increased its stake in shares of Smith & Nephew by 60.2% in the first quarter. Ridgewood Investments LLC now owns 78,178 shares of the medical equipment provider’s stock valued at $1,983,000 after buying an additional 29,378 shares in the last quarter. Nomura Holdings Inc. acquired a new stake in Smith & Nephew in the 4th quarter valued at about $887,000. Goldman Sachs Group Inc. raised its stake in shares of Smith & Nephew by 3.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 1,343,712 shares of the medical equipment provider’s stock worth $36,656,000 after acquiring an additional 44,445 shares during the last quarter. Syon Capital LLC acquired a new position in shares of Smith & Nephew during the fourth quarter worth approximately $356,000. Finally, Clear Street Markets LLC grew its stake in shares of Smith & Nephew by 120.9% during the fourth quarter. Clear Street Markets LLC now owns 175,006 shares of the medical equipment provider’s stock valued at $4,774,000 after purchasing an additional 95,765 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on SNN shares. UBS Group upgraded shares of Smith & Nephew from a “neutral” rating to a “buy” rating in a research report on Wednesday, June 5th. StockNews.com lowered Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research note on Monday, May 13th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy”.

Smith & Nephew Stock Performance

Smith & Nephew stock opened at $24.78 on Friday. Smith & Nephew plc has a fifty-two week low of $21.52 and a fifty-two week high of $32.28. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.77 and a quick ratio of 0.72. The company’s 50 day simple moving average is $25.17 and its 200 day simple moving average is $26.26.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.